Significant Ownership of GILEAD SCIENCES, INC.
- Signature - Title
- /s/ Andrew D. Dickinson - Andrew D. Dickinson / Chief Financial Officer
- Location
- Foster City, CA
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by GILEAD SCIENCES, INC..
Follow Filing Activity
Follow GILEAD SCIENCES, INC. and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
Useful next steps after a schedule filing
Use the page below that answers the next obvious question about this reporting manager or security.
- Latest 13D/G reports to compare this manager with other current ownership disclosures.
- Latest insider ownership reports if you want insider activity alongside the beneficial ownership record.
- Latest 13F portfolio filings for broader institutional context.
- Latest investment quarter holder pages when the next step is security-level holder history.
Significant Ownership of GILEAD SCIENCES, INC.
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| ACLX | Arcellx, Inc. | Common Stock, par value $0.001 | 100% | $11,482 | -$771,671,118 | 100 | -100% | GILEAD SCIENCES, INC. | 28 Apr 2026 |
| GLPG | Galapagos NV | Ordinary Shares, no par value | 30% | $555,786,955 | 20,981,010 | Gilead Sciences, Inc. | 07 Jan 2025 | ||
| ASMB | ASSEMBLY BIOSCIENCES, INC. | Common Stock, par value $0.001 | 29% | 4,505,391 | +104% | GILEAD SCIENCES, INC. | 08 Aug 2025 | ||
| RCUS | Arcus Biosciences, Inc. | Common Stock, par value $0.0001 | 26% | $427,376,736 | 31,424,760 | 0% | GILEAD SCIENCES, INC. | 03 Nov 2025 | |
| XLO | Xilio Therapeutics, Inc. | Common Stock, par value $0.0001 per share | 20% | $9,581,667 | +$2,576,464 | 14,517,678 | +37% | GILEAD SCIENCES, INC. | 31 Dec 2025 |
| KLRS | Kalaris Therapeutics, Inc. | Common Stock, $0.0001 per value | 3.9% | $4,715,740 | 723,273 | GILEAD SCIENCES, INC. | 18 Mar 2025 | ||
| IKNA | Ikena Oncology, Inc. | Common Stock | 3.6% | $1,612,591 | 1,521,312 | GILEAD SCIENCES INC | 31 Dec 2024 | ||
| CYPH | CYPHERPUNK TECHNOLOGIES INC. | Common Stock, par value $0.001 per share | 0% | $0 | 0 | GILEAD SCIENCES, INC. | 31 Dec 2025 |
Schedules 13D/G Reported by GILEAD SCIENCES, INC.:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.